Category Archives: Global News Feed

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 2022 Jefferies Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a presentation at 8:00 am Eastern Time on Friday, June 10, 2022, at the Marriott Marquis in New York, New York. Drs. Lim and Chacko will also participate in one-on-one investor meetings.

The rest is here:
Erasca to Present at the 2022 Jefferies Healthcare Conference

MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that management will participate at two upcoming conferences in June:

The rest is here:
Elucida Oncology to Present at Two Upcoming Conferences

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the first subject was dosed in a Phase I clinical study (NCT05364840) of its oral main viral protease (Mpro) inhibitor, STI-1558.

See the original post here:
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and...

Company announcement – No. 26 / 2022

Read more from the original source:
Zealand Pharma completes registration of capital increase

See the article here:
Bavarian Nordic Conference Call: General Monkeypox Update

Ad hoc announcement pursuant to Art. 53 LR

Read the original:
Santhera Announces Corporate Calendar Update

See the article here:
Virbac : Declaration of the number of shares and voting rights 05/2022

Saint-Herblain (France), June 3, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Jefferies Healthcare Conference which will take place from June 8 to 10, 2022 in New York.

See original here:
Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare Conference

SYDNEY, AUSTRALIA, June 04, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces new data from 1st line NSCLC patients (Part A) of the Phase II TACTI-002 trial evaluating Immutep’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in 114 patients.

Go here to read the rest:
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

See the rest here:
Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2022.